Journals / Medicine Science / 2021 / Cilt: 10 - Sayı: 4

Lipase inhibitor orlistat: An old but still effective weapon

Pages
1406–1411
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mean weight loss values of the patients using orlistat in the 1st, 2nd and 3rd month were found as - 3.6 ± 0.5 kg, -2.2 ± 0.1 kg and -1.8 kg, respectively (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nowadays, the pharmacological treatment of obesity has increased its significance due to the failure of conventional obesity treatments.
📊
Key Findings & Data:A total of 100 patients with body mass index (BMI-kg/m2) of > 40, who were regularly followed up every month and compliant with their treatment (diet, exercise and orlistat) were included in the study.
💡
Conclusion & Impact:Mean weight loss values of the patients using orlistat in the 1st, 2nd and 3rd month were found as - 3.6 ± 0.5 kg, -2.2 ± 0.1 kg and -1.8 kg, respectively (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Nowadays, the pharmacological treatment of obesity has increased its significance due to the failure of conventional obesity treatments. Thus, Orlistat which is a lipase inhibitor is being used as an anti-obesity medication in many countries. In this study, the effect of Orlistat on weight loss and metabolic parameters in Turkish female patients was evaluated. Female patients with diagnosis of obesity who were followed up in Kutahya Training and Research Hospital were evaluated via retrospective observation. A total of 100 patients with body mass index (BMI-kg/m2) of > 40, who were regularly followed up every month and compliant with their treatment (diet, exercise and orlistat) were included in the study. Monthly values of weight loss and BMI, along with baseline - 12th week values of fasting blood glucose, insulin, glycated hemoglobin (HBA1c), lipid profile, creatinine, aspartate aminotransferase, alanine aminotransferase and thyroid- stimulating hormone of patients who received orlistat 120 mg three times a day for 12 weeks in addition to diet and exercise,were evaluated. Mean weight loss values of the patients using orlistat in the 1st, 2nd and 3rd month were found as - 3.6 ± 0.5 kg, -2.2 ± 0.1 kg and -1.8 kg, respectively (p

🔖

Cite This Article

Aydin, B., Onbasi, K. (2022). Lipase inhibitor orlistat: An old but still effective weapon. Medicine Science, Cilt: 10 - Sayı: 4, 1406–1411. https://ajindex.com/articles/579701

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Frühbeck G, Toplak H, Woodward E, et al. Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6:117-20
  2. Yumuk V, Frühbeck G, Oppert JM, et al. An EASO position statement on multidisciplinary obesity management in adults. Obes Facts. 2014;7:96- 101
  3. Saunders KH, Umashanker D, Igel LI, et al. Obesity Pharmacotherapy. Med Clin North Am. 2018;102:135-48
  4. Srivastava, G, Apovian, C. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14:12-24
  5. Cahill A, Lean MEJ: Review article: malnutrition and maltreatment: a comment on orlistat for the treatment of obesity. Aliment Pharmacol Ther. 1999;13:997-1002
  6. Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metabol Disord. 2001;25:1713-21
  7. Torgerson J S, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61
  8. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321-6
  9. Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31:53-65
  10. Wisher D. Martindale: The Complete Drug Reference. 37th ed. J Med Libr Assoc. 2012;100:75-6
  11. Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother. 2000;34:1066-9
  12. Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315:2424-34
  13. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet. 1998;352: 167-72
  14. Jacob S, Rabbia M, Meier MK, et al. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11:361-71
  15. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treat